Transcatheter Aortic Valve Replacement — Net Sales
Edwards Lifesciences Transcatheter Aortic Valve Replacement — Net Sales increased by 3.2% to $1.20B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.4%, from $1.05B to $1.20B. Over 4 years (FY 2021 to FY 2025), Transcatheter Aortic Valve Replacement — Net Sales shows an upward trend with a 7.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong clinical adoption and market share growth in minimally invasive heart procedures, while a decrease may signal increased competition, market saturation, or shifts in physician preference.
Detailed definition
This metric represents the total revenue generated from the sale of transcatheter heart valve replacement systems design...
Peer comparison
Comparable to revenue from structural heart or interventional cardiology segments at major medical device competitors, focusing on the shift from open-heart surgery to catheter-based interventions.
ew_segment_transcatheter_aortic_valve_replacement_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $901.50M | $857.80M | $871.50M | $881.30M | $906.90M | $862.30M | $867.70M | $947.90M | $991.60M | $960.90M | $979.40M | $1.01B | $1.04B | $1.02B | $1.04B | $1.05B | $1.13B | $1.15B | $1.16B | $1.20B |
| QoQ Change | — | -4.8% | +1.6% | +1.1% | +2.9% | -4.9% | +0.6% | +9.2% | +4.6% | -3.1% | +1.9% | +2.9% | +3.0% | -1.5% | +1.3% | +1.0% | +8.1% | +1.7% | +0.9% | +3.2% |
| YoY Change | — | — | — | — | +0.6% | +0.5% | -0.4% | +7.6% | +9.3% | +11.4% | +12.9% | +6.3% | +4.7% | +6.5% | +5.8% | +3.8% | +8.9% | +12.4% | +12.0% | +14.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's transcatheter aortic valve replacement — net sales?
- Edwards Lifesciences (EW) reported transcatheter aortic valve replacement — net sales of $1.20B in Q1 2026.
- How has Edwards Lifesciences's transcatheter aortic valve replacement — net sales changed year-over-year?
- Edwards Lifesciences's transcatheter aortic valve replacement — net sales increased by 14.4% year-over-year, from $1.05B to $1.20B.
- What is the long-term trend for Edwards Lifesciences's transcatheter aortic valve replacement — net sales?
- Over 4 years (2021 to 2025), Edwards Lifesciences's transcatheter aortic valve replacement — net sales has grown at a 7.0% compound annual growth rate (CAGR), from $3.42B to $4.49B.
- What does transcatheter aortic valve replacement — net sales mean?
- Total revenue earned from the sale of transcatheter heart valve replacement medical devices.